Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole/Escitalopram Combination in MDD
NCT01111539Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in major depressive disorder (MDD) (5 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Week 14. Started Jul 2010; status: terminated.
02
Drugs
aripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01111539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111539.